Severe Calcinosis in Limited Cutaneous Systemic Sclerosis.

Authors:
Naoho Takizawa
Naoho Takizawa
Chubu Rosai Hospital
Yoshiro Fujita
Yoshiro Fujita
Chubu Rosai Hospital
Japan

Intern Med 2017 09 21;56(18):2541. Epub 2017 Aug 21.

Department of Rheumatology, Chubu Rosai Hospital, Japan.

Download full-text PDF

Source
http://dx.doi.org/10.2169/internalmedicine.8841-17DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5643192PMC
September 2017
2 Reads

Publication Analysis

Top Keywords

limited cutaneous
4
calcinosis limited
4
systemic sclerosis
4
cutaneous systemic
4
severe calcinosis
4
sclerosis
1
cutaneous
1
limited
1
severe
1
systemic
1

Similar Publications

Increased urinary pyridinoline cross-link compounds of collagen in patients with systemic sclerosis and Raynaud's phenomenon.

Rheumatology (Oxford) 2001 Feb;40(2):140-6

Research Institute of Rheumatic Diseases, Piest'any, Slovak Republic.

Objective: To study concentration changes in collagen degradation markers in patients with diffuse and limited cutaneous systemic sclerosis and patients with scleroderma-related diseases.

Methods: Pyridinoline cross-link compounds were analysed in urine samples using high-performance liquid chromatography. Samples were analysed for pyridinoline (Pyr), deoxypyridinoline (Dpyr) and soft-tissue pyridinoline (stPyr) in patients with diffuse cutaneous systemic sclerosis (dcSSc, n=23) and limited cutaneous systemic sclerosis (lcSSc, n=48) and in patients with scleroderma-related diseases such as primary Raynaud's phenomenon (pRP, n=16) and secondary Raynaud's phenomenon (sRP, n=14). Read More

View Article
February 2001

Systemic sclerosis sine scleroderma and calcinosis cutis: report of a rare case.

Clin Rheumatol 2010 Feb 17;29(2):215-9. Epub 2009 Oct 17.

Department of Dermatology, Venereology and Leprosy, Indira Gandhi Medical College, Shimla, 171001, Himachal Pradesh, India.

Systemic sclerosis sine scleroderma is a rare form of limited cutaneous scleroderma. These patients manifest without cutaneous involvement, but do not differ in its clinical or laboratory features and prognosis from classical systemic sclerosis. In the absence of cutaneous signs/symptoms, its diagnosis is delayed leading to morbidity. Read More

View Article
February 2010

[Botulinum toxin type A contribution in the treatment of Raynaud's phenomenon due to systemic sclerosis].

Ann Chir Plast Esthet 2013 Dec 26;58(6):658-62. Epub 2011 Dec 26.

Service de chirurgie de la main, CHU Conception, 145, boulevard Baille, 13005 Marseille, France.

Aims: Raynaud's phenomenon is a vasospastic disorder of the extremities that can lead, in the hands, to pain, disability, ischemic ulcers and digital chronic ischemia. Medical and surgical current treatments are not fully effective while causing side effects. Recent studies have emphasized the value of botulinum toxin type A (BTX A) in the management of primary Raynaud's phenomenon. Read More

View Article
December 2013

Measurement of cold challenge responses in primary Raynaud's phenomenon and Raynaud's phenomenon associated with systemic sclerosis.

Ann Rheum Dis 1992 Nov;51(11):1193-6

Rheumatic Diseases Centre, University of Manchester, Hope Hospital, Salford, United Kingdom.

Using computed thermography continuous temperature recordings were made before and after cold challenge of the fingers of control subjects and patients with primary Raynaud's phenomenon and Raynaud's phenomenon associated with systemic sclerosis. Basal skin temperature measurements (Tpre) were significantly lower in patients with primary Raynaud's phenomenon and Raynaud's phenomenon associated with systemic sclerosis than in the controls. Temperatures immediately after cold challenge (T0) were significantly lower in patients with primary Raynaud's phenomenon and Raynaud's phenomenon associated with systemic sclerosis than in controls. Read More

View Article
November 1992